Application Detail

Description of Medical Service

Brexucabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.

Description of Medical Condition

Relapsed or refractory mantle cell lymphoma is an aggressive subtype of non-Hodgkin lymphoma

Reason for Application

Highly Specialised Therapy - National Health Reform Agreement

Medical Service Type

Therapeutic technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 1088 KB)
Application Form (Word 345 KB)

Consultation Survey

Consultation Survey (PDF 559 KB)
Consultation Survey (Word 71 KB)

PICO Confirmation

-

Assessment Report

-

Public Summary Document

Public Summary Document (PDF 929 KB)
Public Summary Document (Word 531 KB)

Meetings for this Application

PASC

Expedited – Bypassing PASC

ESC

10-11 June 2021

MSAC

29-30 July 2021
29 July 2023